AmoyDx specialise in molecular diagnostics and precision medicine, with a strong emphasis on developing advanced diagnostic tools for cancer and infectious diseases. Their product range features assays powered by PCR and next-generation sequencing (NGS) technologies, designed to identify genetic mutations, biomarkers, and other molecular indicators essential for guiding targeted therapies.
Some of their key offerings include:
- Pan Lung Cancer PCR Panel: Detect mutations across 11 actionable biomarkers relevant to non-small cell lung cancer (NSCLC), including genes like EGFR, ALK, ROS1, and KRAS. The panel covers 167 variants, including DNA mutations and RNA fusions.
- Multi-Gene Mutations Detection Kit: Detect up to 118 variants in genes such as EGFR, KRAS, NRAS and BRAF with a kit designed to assist in identifying therapeutic targets for NSCLC​.
- HRD Focus Panel: Assess biomarkers related to PARP inhibitors (PARPi) in your targeted therapy research with this reliable and cost-effective option. Using proprietary HANDLE technology, the Genomic Scar Score (GSS) algorithm, and the AmoyDx NGS Data Analysis System (ANDAS), the HRD Focus assay integrates smoothly into laboratory workflows. Our approach ensures efficient, end-to-end solutions with under one hour of hands-on time, delivering high-quality genomic instability assessments and automated, secure data analysis.
- BRCA Pro Panel: Detect germline/somatic SNVs/Indels as well as germline large rearrangements (LRs) from either whole blood or FFPE tissue samples. This panel comprehensively covers all protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes.
